Notas de prensa

A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants

Japón aprueba los fortificantes de Prolacta Bioscience, elaborados 100% con leche materna

ARK Invest UCITS ICAV - Net Asset Value(s)

Ashoka WhiteOak Emerging Markets Trust Plc - Monthly Update - January 2026

Fair Oaks Capital ETFs - Net Asset Value(s)

Moonpig Group Plc - Transaction in Own Shares

Nordea ICAV ETF - Net Asset Value(s)

Oxford Instruments Plc - Transaction in Own Shares

Mondi Plc - Final Results

Robeco UCITS ICAV - Net Asset Value(s)